Ayala Pharmaceuticals Inc (fka ADXS)

[fbg0316]

Gantor, it's clear O'Connor didn't have a well thought out plan. He simply saw an endless blank check via secondary offerings and his foremost priority was pushing unearned bonus comp through the proxy process using his lawyering skills IMO. Anyone that pushed through the latest comp increase with automatic renewals each year without shareholder consent that he did at a time when shareholder value had eroded as much as it had under his watch had no business being CEO. I think his fiscally reckless mindset permeated across the management team. In watching the Ireland video, I found it disappointing that when asked about the company's business objectives Bonstein said they didn't want to have to rely on the capital markets at some point moving forward, then she went on to talk about how the company planned to start even more trials at end of the this year, but she never once mentioned the company's investors or generating an ROI. So who was going to pay of all these new trials she was talking about? I guess "the capital markets." There was a clear disconnect through the whole video and lack of sense of fiduciary awareness management had toward the company's shareholders IMO. As such, Dan's gone now for the better of the company and its investors.